Caricamento azienda
Just reported
Q3 2026 results
From Progyny's results release of 4 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
341,3M USD
+8,9% y/y
-2,6% q/qGuided
340M USD
midpoint
Within guide+0,4%EPS, GAAP
Actual
0,32 USD
+113% y/y
-5,9% q/qGuided
—
No guide given
Operating income, GAAP
Actual
35,2M USD
+63% y/y
-12% q/qGuided
—
No guide given
Company outlook
Q4 2026
- Revenue344,7M USD – 364,7M USD+11% y/y First given
- EPS, adjusted0,53 USD – 0,58 USDFirst given
Full year 2026
- Revenue1,365B USD – 1,385B USD+6,7% y/y Unchanged
- EPS, adjusted2,09 USD – 2,13 USDRaised +1,9%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Progyny is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Healthcare Plans
Graded A or B and worth $2B or more: A first, then the largest.
CVSCVS Health Corp114,3B USDA
CIThe Cigna Group78,3B USDA
OSCROscar Health, Inc.9,6B USDA
CLOVClover Health Investments, Corp.2,7B USDA
HUMHumana Inc.54,1B USDB
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A- CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 ott 2026CAGraded C, now A
Costruito dai documenti depositati da Progyny, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
